Skip to main content

Table 3 MMP-3, US7 scores, and clinical characteristics of 22 patients with RA being treated with CZP

From: Matrix metalloproteinase-3 and the 7-joint ultrasound score in the assessment of disease activity and therapeutic efficacy in patients with moderate to severe rheumatoid arthritis

 

Weeks (W) after treatment

W0

W2

W12

W24

DAS28

6.17 ± 0.86

4.365 ± 1.12***

3.62 ± 1.32***

3.43 ± 1.26***

US7

8.7 ± 8.61

3.1 ± 3.09**

2.35 ± 2.85**

2.1 ± 2.51**

MMP-3

214.8 ± 160.4

94.11 ± 74.96***

98.86 ± 114.7***

122.7 ± 167.7*

CRP

12.40 ± 15.01

6.05 ± 7.338

5.45 ± 8.27**

6.5 ± 15.22

Anti-CCP

363.0 ± 385.6

386.7 ± 454.2

339 ± 374.2

300.3 ± 323.7

HAQ

22.2 ± 14.7

13.85 ± 10.64***

12.5 ± 9.95**

12.9 ± 10.7***

ESR

60.35 ± 22.78

38.95 ± 16.96***

29.75 ± 14.59***

37.0 ± 21.8***

Synovitis

3.70 ± 3.511

2.35 ± 2.98*

2.25 ± 2.845*

1.3 ± 2.658**

Synovial blood flow

1.85 ± 2.368

0.85 ± 1.63*

0.65 ± 1.424*

0.4 ± 0.821**

Tenosynovitis

0.25 ± 0.71

0.05 ± 0.22

0.05 ± 0.23

0

Tenosynovial blood flow

0.25 ± 0.71

0

0

0

Bone erosion

0.65 ± 1.13

0.5 ± 1.0

0.45 ± 0.99

0.3 ± 0.57

  1. RA rheumatoid arthritis, CZP certolizumab pegol, CCP cyclic citrullinated peptide, CRP C-reactive protein, DAS28 disease activity score in 28 joints, ESR erythrocyte sedimentation rate, HAQ health assessment questionnaire, MMP-3 matrix metalloproteinase-3, US7 7-joint ultrasound score
  2. Compared with the baseline level (W0), ***p < 0.001, **p < 0.01, *p < 0.05